ImmuCell Corp
NASDAQ:ICCC
Relative Value
The Relative Value of one ICCC stock under the Base Case scenario is 7.68 USD. Compared to the current market price of 5.14 USD, ImmuCell Corp is Undervalued by 33%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
ICCC Competitors Multiples
ImmuCell Corp Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
ImmuCell Corp
NASDAQ:ICCC
|
39.8m USD | 2.3 | -6.9 | -16.3 | -8.6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
280.4B USD | 5.2 | 58.2 | 12.7 | 19.3 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
146.3B USD | 5.2 | 21.7 | 16.2 | 24.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.3 | 28.2 | 22.6 | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
97.9B USD | 7.5 | 24.8 | 16.4 | 18 | ||
AU |
CSL Ltd
ASX:CSL
|
132.9B AUD | 6.1 | 35.1 | 21.3 | 26.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
82.8B USD | 3.1 | 14.6 | 8 | 10.3 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
42.6B USD | 6.2 | -9 | -9.6 | -8.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.6B USD | 3.2 | 27.2 | 14.7 | 18.2 | ||
IE |
Horizon Therapeutics PLC
NASDAQ:HZNP
|
26.6B USD | 7.3 | 60.8 | 27.9 | 47 |